Why are some cervical cancer vaccines ＂hard to find one vaccine＂？ Many people are vaccinated internationally.

　　Xinhua News Agency, Shanghai, May 24 (Reporter Gong Wen, Qiu Yi) Recently, news came from many places that it was difficult to vaccinate the tetravalent human papillomavirus vaccine (hereinafter referred to as HPV vaccine) for preventing cervical cancer. At the same time, "the suspension of the supply of the nine-valent HPV vaccine in the Hong Kong market" also attracted many social concerns. The reporter launched an investigation into this.

　　"One seedling is hard to find": international vaccination

　　"I started to make an appointment to vaccinate the tetravalent HPV vaccine at the community health center near my home at the end of 2017. I haven’t heard anything for almost half a year, and Shanghai hasn’t started to supply the newly approved nine-valent HPV vaccine. I just want to go to Hong Kong to vaccinate the nine-valent HPV vaccine." Shanghai citizen Sun Huining said.

　　However, after contacting several medical institutions, she found that the supply situation in Hong Kong was not optimistic. Even if some people received the first injection, they could not guarantee the second injection on time. After some consideration, she also chose this road because she saw her friends go to South Korea for vaccination.

　　Sun Huining introduced that she was vaccinated with a nine-valent HPV vaccine in a public medical institution in South Korea, with a total of about 800,000 won (more than 4,700 yuan) in three injections. At the time of the first vaccination, she paid the full amount as required and received a written certificate marked with the supplier Merck.

　　It is understood that in the mainland, the nine-valent HPV vaccine is suitable for women aged 16 to 26, in Hong Kong, it is suitable for people over 9 years old (not limited to men and women), and in South Korea, it is suitable for people aged 9-26 (not limited to men and women). Although the applicable age of vaccines in different regions is different, the management methods may also be different, but as long as they can be hit, many people prefer to "stay near and seek far".

　　Sun Huining admits that he also wants to vaccinate in China, saving time and effort, but the main reason for going abroad for vaccination is that he doesn’t want to wait. Judging from the long queue of tetravalent HPV vaccine, it is worried that it will take a long time after the nine-valent HPV vaccine is supplied in many places in China. It is worth mentioning that during this "trip", Sun Huining also met several China friends of her age. After communication, we found that everyone’s ideas were basically the same: "Fight early and feel at ease".

　　Merck: It will speed up production and increase production capacity.

　　At present, there are three kinds of HPV vaccines listed in the world: bivalent, tetravalent and nine-valent, and "valence" represents the virus types that the vaccine can prevent. Bivalent vaccine can prevent HPV16 and HPV18 infection, tetravalent vaccine can prevent HPV 6, 11, 16 and 18 infection, and nine-valent vaccine can prevent five more kinds on the basis of tetravalent vaccine. According to reports, bivalent and tetravalent vaccines can prevent and control the risk of cervical cancer by 84.5%, and the nine-valent vaccine can prevent cervical cancer by 92.1%.

　　Among them, bivalent HPV vaccine is provided by GlaxoSmithKline, and tetravalent and nonavalent HPV vaccines are provided by Merck.

　　— — In an interview with Xinhua News Agency’s "China Net" reporter, Merck said that it would speed up production in view of the shortage of four-valent HPV vaccines in the Mainland and nine-valent HPV vaccines in Hong Kong. The vaccine production process is complex and the production cycle is long. Under the premise of ensuring the quality and safety of the vaccine, the company is increasing investment, improving production capacity and strengthening the supply capacity of HPV vaccine.

　　According to Merck, since November 2017, the company’s Hong Kong team has been advising doctors to keep follow-up injections for consumers who have already received the first dose of HPV vaccine. At present, the nine-valent HPV vaccine is still available in the Hong Kong market. Merseyside Hong Kong will release further information in time.

　　— — Merck said that according to the announcement of the price negotiation results of the second kind of vaccine supplement project in Hainan Province, the winning bid price of the nine-valent HPV vaccine was 1,298 yuan/piece. At present, the bidding access of various provinces and cities is under discussion. Once more exact information is available, the public will be informed in time by the publicity of relevant governments.

　　"The rapid approval of the nine-valent HPV vaccine for listing is based on the clinical trial data before the relevant regulatory authorities adopted the nine-valent HPV vaccine for listing in overseas markets. At present, we are applying for clinical trials of other age groups in line with national requirements. " Merck said.

　　— — There is no shortage of bivalent HPV vaccine and the current market supply is normal. According to GlaxoSmithKline, "sirrah Shi" has received a good response in vaccination among school-age women since it was listed in July 2017. In the nine months since the launch of the adult vaccine service project with Ali Health, more than 300,000 potential vaccinators have consulted online, and the actual number of people who have made appointments has reached 50,000.

　　"At present, the bidding work of 28 provinces and cities across the country has been completed. According to the bidding timetable of each province, the bidding of the remaining provinces will be completed. China is one of our key markets and will spare no effort to ensure an adequate and stable supply of cervical cancer vaccine to meet the vaccination needs of the majority of women of school age. " GlaxoSmithKline said.

　　Tertiary prevention: screening and early treatment are still indispensable.

　　As a common malignant tumor that seriously threatens women’s health, cervical cancer ranks in the forefront of female malignant tumors all over the world. Dr. Zhi Li from the Institute of Immunization Planning of the Shanghai Center for Disease Control and Prevention said that vaccination is of great significance for women, especially high-risk groups, to prevent cervical cancer.

　　Zhao Dong, director of the Cervical Department of Shanghai First Maternal and Infant Health Hospital, said that HPV vaccination is mainly to prevent high-risk groups (mainly young women) from contracting high-risk HPV, and men joining the vaccination team can also indirectly protect them.

　　It is understood that bivalent, tetravalent and nine-valent HPV vaccines approved in mainland China are suitable for women aged 9 to 25, 20 to 45 and 16 to 26 respectively. Vaccines are usually administered in three injections for a total of six months to be effective.

　　For the applicable population of some vaccines and the timetable for vaccination in the future, many people appeal that although the nine-valent HPV vaccine in the mainland has been approved for listing very quickly, it is hoped that the applicable age of the nine-valent HPV vaccine can be accelerated and can be included in medical insurance. Most importantly, I hope that the relevant manufacturers can increase their production capacity in time to meet the drug demand of more people.

　　According to many experts in the industry, there are hundreds of types of HPV virus, and no matter which HPV vaccine, it can’t cover all carcinogenic HPV. There is a long way to go to improve the three-level prevention system of cervical cancer, from the first-level vaccination to the second-level enhanced screening of cervical cancer and the third-level early diagnosis and treatment.